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Introduction: Intermittent hypoxemia (IH) is defined as episodic drops in oxygen saturation (SpO2). Preterm infants are at increased risk for IH due to their immature respiratory
control/apnea of prematurity. The clinical relevance of IH is a relatively new observation
with rising evidence linking IH to neonatal morbidities and long-term impairment. Hence,
assessing factors that influence IH in preterm infants is imperative. Given the epidemic of
opioid misuse in the USA, there is an urgent need to understand the impact of prenatal
opioid exposure on neonatal outcomes. Hence, we wanted to assess the relationship
between isolated prenatal opioid exposure and IH in preterm infants.
Methods: In order to accurately calculate IH, SpO2 data were prospectively collected
using high-resolution pulse oximeters during the first 8 weeks of life in preterm infants
less than 30 weeks gestational age. Data related to prenatal opioid misuse were retrospectively collected from medical charts. Infants with tobacco or poly-drug exposure
were excluded. The primary outcome measure is percent time spent with SpO2 below
80% (%time-SpO2 < 80). The secondary outcome measure is the number of severe IH
events/week with SpO2 less than 80% (IH-SpO2 < 80).
Results: A total of 82 infants with isolated opioid exposure (n = 14) or who were
unexposed (n = 68) were included. There were no significant differences in baseline
characteristics between opioid exposed and unexposed groups. There was a statistically significant increase of 0.23 (95% CI: 0.03, 0.43, p = 0.03) in mean of the square
root of %time-SpO2 < 80. The number of IH-SpO2 < 80 events was higher in the opioid
exposed group (mean difference = 2.95, 95% CI: −0.35, 6.25, p-value = 0.08), although
statistical significance was not quite attained.
Conclusion: This study shows that preterm infants prenatally exposed to opioids have
increased IH measures compared to unexposed infants. Interestingly, the increased IH in
the opioid exposed group persists beyond the immediate postnatal period.
Keywords: prenatal, opioid exposure, opiates, intermittent hypoxemia, apnea, preterm infants

Abbreviations: GA, gestational age; IH, intermittent hypoxemia; NICU, neonatal intensive care unit; SIDS, sudden infant death
syndrome; SpO2, oxygen saturation; THC, tetrahydrocannabinol.
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INTRODUCTION

as percent time spent with SpO2 below 80% (%time-SpO2 < 80).
The secondary outcome measure was defined as the number of
severe IH events with SpO2 less than 80% (IH-SpO2 < 80). Other
outcome measures such as length of stay and neonatal morbidities were collected.
Pulse oximeters were equipped with serial data recorders
(Acumen Instruments Corp.) for continuous data collection.
Novel programs were utilized to filter and analyze data (Matlab,
Natick, MA, USA) (1, 33). Data with artifacts were excluded.
Only SpO2 data with good signal were included in the analyses.
Preterm infants less than 30 weeks GA were included. Infants
with major congenital malformations were excluded.
Data related to substance misuse and tobacco use were retrospectively collected from medical charts. If a mother chronically used prenatal opioids and/or the maternal/neonatal drug
screens were positive for opioids, then the infant was considered
for screening. Infants were then excluded from the study if the
mother used tobacco, alcohol, or other drugs (such as cannabis);
i.e., in order to assess for isolated opioid exposure, patients with
any other exposure were excluded. Infants in our cohort who were
not exposed to opioids, tobacco, or other drugs served as controls.
Neonatal meconium or urine drug screens are performed in the
immediate newborn period. Positive drug screens due to opioids
and other medications used for pain or sedation during delivery
were excluded, as they do not represent prenatal misuse. Tobacco
and alcohol use were collected from mothers’ medical records, as
the toxicology screens at our hospital do not test for alcohol or
tobacco exposure. The study was approved by the University of
Kentucky Institutional Review Board, and informed consent was
obtained prior to SpO2 data acquisition.

Intermittent hypoxemia (IH) is defined as brief, episodic drops in
oxygen saturation (SpO2) (1, 2). Preterm infants are at increased
risk for IH due to their respiratory control instability/apnea of
prematurity superimposed on immature lung structure/function. IH in preterm infants can persist beyond discharge from
the neonatal intensive care unit (NICU) (3). Brief episodes of
oxygen desaturations may seem clinically insignificant, but
these IH episodes, occurring up to hundreds of times per day,
have a cumulative effect on neonatal morbidity and mortality.
There is ample evidence showing a significant effect of IH on
neurocognitive handicap, decreased neuronal integrity, increased
inflammation and oxidative stress, and impaired growth (4, 5).
Furthermore, IH has been linked to severe retinopathy of prematurity and long-term neurodevelopmental impairment such
as worse language and motor outcomes (2, 6–9). The clinical
relevance of IH is a relatively new observation with the advent of
high-resolution pulse oximeters and assessing factors that influence IH is imperative.
There is a rise in substance misuse in the USA reaching a
nationwide epidemic (10–15). There is an urgent need to
understand the impact of prenatal opioid exposure on neonatal
outcomes (5). Opioid exposure is associated with long-term neurobehavioral and developmental impairment in infants (16–23).
Opioids are known to suppress breathing and respiratory effort
especially in neonates (24). Since most mothers who misuse
opioids have also been found to smoke and use poly-drugs
that affect breathing pattern, it has been challenging to assess
the isolated effect of prenatal opioid exposure on respiratory
outcomes. Prenatal tobacco exposure alters respiratory control
and worsens lung function (25–29). Prenatal exposure to other
illicit drugs such as cocaine perturbs maturation of respiratory
control, resulting in disruption of postnatal respiration (30).
Only few studies were able to assess the effect of isolated opioid
exposure on neonatal respiratory outcomes. However, these
studies included mostly later preterm and term infants or were
limited to short monitoring times and small sample sizes (31,
32). In this study, we utilize continuous high-resolution pulse
oximeters to assess the relationship between isolated prenatal
opioid exposure and IH in preterm infants during the first
2 months of life.

Statistical Analysis

Descriptive statistics for continuous variables are presented as
either the mean with SD or median with interquartile range, and
frequencies and percentages are given for categorical variables.
Two-sample t-tests and Wilcoxon two-sample tests were used
to compare opioid exposure to non-exposure with respect to
continuous variables, and chi-square or Fisher’s exact tests were
used for categorical variables. To compare opioid exposure to
non-exposure with respect to IH measures over time, we utilized
multivariate Gaussian linear modeling in order to account for
repeated measurements from subjects, and to adjust for the
potential confounders of GA, birth weight, APGAR score at
5 min of life, gender, and the use of prenatal steroids. In order to
meet statistical assumptions in these models, the square root of
the IH measures was taken. Furthermore, weekly observations
were weighted by the percentage of time IH was tracked during
the given week. Analyses were conducted in SAS version 9.4 (SAS
Institute, Cary, NC, USA), and all tests were two-sided with a 5%
significance level.

MATERIALS AND METHODS
Study Design and Data Collection

Oxygen saturation data were prospectively collected from 130
preterm infants less than 30 weeks gestational age (GA) admitted
to our level 4 NICU between November 2014 and April 2017.
We used high-resolution pulse oximeters (Radical 7: Masimo,
Irvine, CA, USA) set at 2 s averaging time and 1 Hz sampling rate
to continuously monitor patients during the first 8 weeks of life.
In order to differentiate intermittent from sustained hypoxemia,
we included events between 4 and 180 s (1). The exact threshold
below which IH is clinically significant is controversial. A drop in
SpO2 to less than 80% is widely considered to be clinically relevant
(1, 2, 6). Therefore, the primary outcome measure was defined
Frontiers in Pediatrics | www.frontiersin.org

RESULTS
Of the 127 infants in our database with complete data sets, 19.7,
29.1, and 4.7% were prenatally exposed to opioids, tobacco, and
cannabis, respectively. None were exposed to alcohol, cocaine,
and other illicit drugs. Opioid exposed infants were positive for
2
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group (p = 0.35). The median length of stay was 17 days longer
in the opioid group (85 days) compared to unexposed group
(68 days); however, the results were not statistically significant
(p = 0.32).
There was a statistically significant increase in our primary
outcome measure, %time-SpO2 < 80, as represented in Figure 2.
The estimated difference in the means of the square root of
%time-SpO2 < 80 was 0.23 (95% CI: 0.03, 0.43, p = 0.03). The
mean number of IH events was estimated to be 2.95 (95% CI:
−0.35, 6.25, p-value = 0.08) higher in the opioid exposed group,
as represented in Figure 3; however, this did not reach statistical
significance. Note that these results represent the square root of
means in order to meet statistical assumptions in these models;
estimated medians for IH measures are calculated using our
model results and are presented in Figures 2B and 3B. Given
increased death in the unexposed group, we then analyzed data
excluding deaths, and results were similar. Specifically, there
was a statistically significant increase in our primary outcome
measure (%time-SpO2 < 80) in the opioid exposed compared to
the unexposed group, with an estimated mean difference (square
root) of 0.24 (95% CI: 0.05, 0.44, p-value = 0.02). Furthermore,
the mean number of IH events was estimated to be 2.98 (95% CI:
−0.20, 6.16, p-value = 0.07) higher in the opioid exposed group,
not quite reaching statistical significance.

buprenorphine metabolites (64%), oxycodone (16%), and other
opioids such as heroin and fentanyl (20%). A total of 82 infants
qualified for analysis as they were either unexposed to any illicit
drug/tobacco (n = 68) or exposed to opioids only (n = 14).
Figure 1 presents the flow diagram for patient eligibility and
exclusion.
There were no significant differences in baseline characteristics
as presented in Table 1. The mean GA was 27 weeks in both groups.
There were no significant differences in birth weight, gender, and
Apgar scores at 5 min of life. The vast majority of infants received
prenatal steroids with no difference between groups. There were
no significant differences in respiratory outcomes and neonatal
morbidities between groups as presented in Table 2. Our cohort
included preterm infants less than 30 weeks GA. Essentially all
infants had respiratory distress syndrome and received surfactant.
Severe bronchopulmonary dysplasia, postnatal steroids use for
lung disease, and oxygen need at 28 days, 36 weeks postmenstrual
age, and at discharge did not differ between opioid exposed and
unexposed groups (all p = NS). Other neonatal morbidities such
as patent ductus arteriosus, late onset sepsis, and necrotizing
enterocolitis did not differ between groups (all p = NS). None
of the exposed infants died versus nine deaths in the unexposed

DISCUSSION
These results suggest that prenatal opioid exposure is associated
with increased IH measures compared to unexposed preterm
infants. This study has two main findings. First, interestingly,
the increased IH measures in opioid exposed infants persisted
beyond the early postnatal period. Preterm infants were continuously monitored with high-resolution pulse oximeters during the
first 2 months of life. Second, we had the unique opportunity to
assess the relationship between isolated opioid exposure and
respiratory instability in preterm infants. It was challenging in the
past to assess the relationship between isolated prenatal opioid
TABLE 2 | Neonatal morbidities and outcomes.

FIGURE 1 | Flow diagram for patient eligibility.
Received surfactant
Respiratory distress syndrome
Oxygen at 28 days of life
Oxygen at 36 weeks corrected age
Oxygen at discharge
Severe bronchopulmonary dysplasia
Postnatal steroids use for lung disease
Pneumothorax
Patent ductus arteriosus
Necrotizing enterocolitis
Late onset sepsis
Mortality
Length of stay (days)

TABLE 1 | Baseline characteristics.

Gestational age (weeks)
Birth weight (g)
Male
Apgar 5 min
Prenatal steroids

Opioid exposed

Unexposed

N = 14

N = 68

27.0 ± 2.1
948 ± 263
6 (43%)
7 (6, 7.5)
12 (86%)

27.0 ± 1.6
928 ± 247
23 (34%)
6 (5, 7)
61 (91%)

p-Value

0.97
0.79
0.54
0.21
0.62

Mean ± SD, median (interquartile range).

Frontiers in Pediatrics | www.frontiersin.org

Opioid
exposed

Unexposed

N = 14

N = 68

14 (100%)
14 (100%)
10 (71%)
7 (50%)
9 (64%)
9 (64%)
6 (43%)
1 (7%)
8 (57%)
0 (0%)
3 (21%)
0 (0%)
85 (59, 101)

62 (91%)
67 (99%)
39 (57%)
19 (28%)
30 (44%)
27 (46%)
19 (29%)
2 (3%)
24 (35%)
2 (3%)
9 (13%)
9 (13%)
68 (56, 91)

p-Value

0.58
1
1
0.26
0.18
0.21
0.35
0.43
0.13
1
0.43
0.35
0.32

Frequency (%), median (interquartile range).
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FIGURE 2 | (A) Preterm infants exposed to prenatal opioids had increased time spent with oxygen saturation less than 80% (%time-SpO2 < 80) compared to
unexposed infants (p = 0.03). The model adjusted for gestational age, birth weight, gender, prenatal steroids, and Apgar scores at 5 min of life. (B) This figure
demonstrates the estimated average %time-SpO2 < 80 medians in both groups calculated using the adjusted model results. Sqrt, square root.

FIGURE 3 | (A) Preterm infants exposed to prenatal opioids did not have a significant increase in number of intermittent hypoxemia (IH) events per week (IHSpO2 < 80) compared to unexposed infants (p = 0.08). The model adjusted for gestational age, birth weight, gender, prenatal steroids, and Apgar scores at 5 min of
life. (B) This figure demonstrates the estimated average IH-SpO2 < 80 medians of opioid exposed versus unexposed preterm infants calculated using the adjusted
model results. Sqrt, square root.

exposure and respiratory outcomes/IH, as the majority of women
who use opioids also smoke or misuse poly-drugs. Given our
cohort demographics, we had the ability to report this association
in infants exposed to opioids only.
Another interesting secondary finding in our study is the
steady increase in IH in the first month of life before plateauing
and then decreasing. This natural progression of IH has been
described before from another cohort of preterm infants less than
28 weeks GA (1, 2). Our study replicates this finding from a new
cohort of preterm infants less than 30 weeks GA. The rise in IH
may be related to peripheral chemoreceptor dysregulation and
development of lung disease (34).
Patients in our opioid exposed and unexposed groups did not
significantly vary in terms of baseline characteristics (such as age,
weight, gender) and neonatal morbidities (such as lung disease,
patent ductus arteriosus, late onset sepsis, and necrotizing
enterocolitis). In addition, we adjusted in the model for factors

Frontiers in Pediatrics | www.frontiersin.org

that may influence oxygenation in preterm infants such as GA
and prenatal steroids. The finding of nine deaths in the unexposed
group compared to no deaths in the opioid exposed group may
be due to chance. Secondary analyses excluding deaths showed
similar results with increased IH in the opioid exposed group. A
significant secondary finding in this study is the high prevalence
of tobacco and drug exposure in our cohort of preterm infants.
The frequency of opioid exposure in our preterm population is
higher than previously reported, thus creating urgency toward
addressing this significant problem in this vulnerable patient
population (10, 12–15).
There are multiple proposed mechanisms by which prenatal
opioid exposure may affect breathing patterns and subsequent
persistent IH in preterm infants. Prenatal opioid exposure alters
the response to carbon dioxide and depresses central respiratory
control centers (31, 35–38); a main driver for respiratory output.
Olsen and Lees demonstrated a blunted response to carbon

4
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dioxide in methadone exposed infants compared to controls
(31). Ali et al. compared the response to hypercarbia among
three groups of term patients who were exposed to tobacco/
substance misuse, tobacco alone, and unexposed controls. The
authors showed a lower increase in central respiratory drive in
response to hypercarbia in infants exposed to substance misuse
as compared to tobacco alone and unexposed controls (35).
Another mechanism that explains our results may be related to
in utero hypoxia related to opioids. Prenatal opioids, especially
street heroin, cause chronic intrauterine hypoxia leading to
brainstem gliosis, resulting in injury to the central respiratory
network. This may lead to respiratory instability and subsequent IH (36). Finally, data from animal models showed that
exposure to opioid agonists caused downregulation of placental
neurotransmitter receptors (39). Abnormalities or depletion
of receptor sites, especially if the same process occurs in the
fetal brain, could impair the function of the normal neonatal
respiratory control network leading to frequent or prolonged
apnea and subsequent IH.
Many studies have assessed the impact of prenatal opioid
exposure on sudden infant death syndrome (SIDS) in infants with
controversial results. This study does not address SIDS; rather, it
focuses on IH, the end result of apnea of prematurity. However,
the mechanism by which prenatal opioid exposure is associated
with increased SIDS and IH may be similar. Although our study
period focused on the inpatient setting, it is plausible that opioid
exposed infants continue to have increased cardiorespiratory
events/IH after discharge. Interestingly, compared to unexposed
infants, opioid exposed infants had a trend toward longer length
of stay (68 versus 85 days, p = NS), which may be related, in part,
to persistent cardiorespiratory events.
A major limitation of this study is that data related to exposure
were retrospectively collected. Another limitation is a lack of
reporting daily caffeine use and daily respiratory support settings.
At our center, virtually all infants with GA less than 30 weeks are
started on caffeine therapy. Furthermore, our study focused on IH
events and lacked reporting of apnea and bradycardia events. Lack
of addressing heart rate is a limitation since bradycardia events
may be associated with poor long-term outcomes (6). Another
limitation is the small sample size; however, our sample size of
isolated opioid exposure is relatively large compared to existing
literature. This is a single center study; hence, our results may not
be generalizable. Finally, we did not compare the long-term neurodevelopmental outcomes for exposed versus unexposed infants.

long-term neurodevelopmental outcomes are imperative. Given
the rising epidemic of opioid misuse in the USA, understanding
the relationship between opioid exposure, IH and long-term
impairment is imperative. A larger prospective study aimed at
understanding these relationships may have a direct impact on
short- and long-term management of preterm infants.
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